Novo Nordisk A/S ’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far higher in the US, where the cost of the drug has prompted a political outcry.
In the UK, the budget-conscious National Health Service spends less than half as much as US payers to prevent one of those health complications with Wegovy, even with discounts factored in, according to data analytics firm Airfinity Ltd. In Germany and Novo’s home market of Denmark, the bill is at least 25% lower.